Phase 2, randomized, double-blind, placebo-controlled study of IC0624 as first-line therapy in patients with active mild to moderate Hidradenitis Suppurativa (HS)
This research is looking into a new treatment, known as IC0624, for people who have mild to moderate Hidradenitis Suppurativa, a long-term skin condition. It's a 'Phase 2' study, meaning it's exploring how well the new medicine works and if it's safe. Some participants will receive the active medication, while others will get a placebo – a dummy tablet that looks the same but contains no medicine. This helps researchers understand the true effects of the new drug. The main goal is to see if the new medicine can significantly improve HS symptoms, like reducing painful lumps and abscesses, within six weeks. Researchers will also look at how it affects pain, quality of life, and any side effects.
At a glance
What is this study about?
This study is designed to investigate a new medication, IC0624, for people living with Hidradenitis Suppurativa, often shortened to HS. HS is a long-term skin condition that causes painful lumps, boils, and abscesses, usually in areas like the armpits, groin, and under the breasts. It's a 'Phase 2' study, which means it's an earlier stage of research where scientists are exploring how effective the new treatment might be and checking for any potential side effects. It's not yet known if this new medication is better than existing treatments.
To make sure the study gives clear results, some participants will receive the active medication, while others will receive a 'placebo'. A placebo is a dummy pill that looks exactly like the real medicine but contains no active ingredients. Neither you nor your study doctor will know whether you're receiving the active drug or the placebo. This is called 'double-blind' and it helps to prevent any bias in the results, ensuring we understand the true effect of IC0624.
The main aim of the study is to see if IC0624 can help reduce HS symptoms by at least 50% within six weeks. Researchers will closely monitor your skin, measure your pain levels, and ask about your quality of life during this period. They will also keep a careful eye on your general health through blood tests to make sure the treatment is safe and well-tolerated. This study is an important step in potentially finding new ways to help people manage their HS.
Key takeaways
- This study is testing a new medication (IC0624) for mild to moderate HS.
- It's a 'double-blind' study, meaning you might get the new drug or a dummy pill.
- The main goal is to see if HS symptoms improve over six weeks.
- Participation involves regular clinic visits, skin checks, and blood tests.
- You must be an adult (18+) with active HS to be considered.
- You can stop participating at any time.
Who may be eligible?
To be considered for this study, you must be an adult aged 18 or over. This study is open to both men and women.
Your Hidradenitis Suppurativa must be active and fall into the mild to moderate category. This means your HS symptoms are currently present and causing you some issues, but not to the most severe degree as judged by the study doctors.
There will be other detailed health checks to make sure this study is safe and suitable for you, which the study team will discuss during your initial appointments.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Do you have a diagnosis of Hidradenitis Suppurativa (HS)?
- Is your HS currently active, and considered mild to moderate by your doctor?
- Are you able to attend regular clinic appointments for six weeks?
What does participation involve?
If you decide to take part, you will be given a medication to take, which could be the new treatment or a dummy pill. You won't know which one you're getting, and neither will the study doctor. You'll need to visit the clinic regularly over six weeks for check-ups. During these visits, the study team will examine your skin to count any active HS lesions, ask you about your pain levels, and you might be asked to fill in questionnaires about how your HS affects your daily life and overall well-being. You'll also have blood tests at the start and end of the study to check your general health. You may also be asked to keep a daily diary of your pain experience and any other medicines you take for your HS. The total duration of your active participation will be six weeks, with follow-up on any observed side effects.
Potential risks and benefits
Locations (1)
- —UnverifiedGermany
Common questions
What is Hidradenitis Suppurativa (HS)?
HS is a long-term skin condition that causes painful lumps, boils, and abscesses, often in places where skin rubs together, like armpits and groin.
What is a 'Phase 2' study?
It's an early stage of research where doctors look at how well a new medicine works for a specific condition and check for any side effects before it can be used more widely.
What does 'double-blind' mean?
It means neither you nor your study doctor will know if you're receiving the new medicine or a dummy pill (placebo). This helps make the study results fair and accurate.
What is a placebo?
A placebo is a tablet that looks exactly like the real medicine but contains no active ingredients. It helps researchers understand the true effects of the new drug.
How long will I be in the study?
Your active participation, including taking the medication and having check-ups, will last for six weeks.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.